An open-labeled, international, multicenter, dose escalating, phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukemia
Latest Information Update: 18 Jul 2023
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 09 Jan 2007 Status change
- 25 Sep 2005 New trial record.